Survival Benefit of Birtamimab in Treating AL Amyloidosis

Morie Gertz, MD, Hematologist, Chair Emeritus Internal Medicine, Mayo Clinic, discusses post hoc analysis data on the survival benefit of birtamimab in high-risk amyloid light chain (AL) amyloidosis in the phase 3 VITAL study. These data were recently presented at the American Society of Hematology Meeting & Exposition (ASH 2022).

Stay Up To Date:

Receive the latest news and developments in treatment and care

Featured Resources

FAQs

1 The Core Members of an Amyloidosis Care Team ?

Find resources, support groups, and organizations that offer information, assistance, and a community for Amyloidosis patients and their families.

2 What Treatment Options are Available for Amyloidosis?

Find resources, support groups, and organizations that offer information, assistance, and a community for Amyloidosis patients and their families.

3 How is Amyloidosis Diagnosed?

Find resources, support groups, and organizations that offer information, assistance, and a community for Amyloidosis patients and their families.

4 What Specialists Are Involved in the Treatment of Amyloidosis?

Find resources, support groups, and organizations that offer information, assistance, and a community for Amyloidosis patients and their families.

Patient Care Center

Survival Benefit of Birtamimab in Treating AL Amyloidosis

Stay Up To Date:

Featured Resources

Caregiver Support : Taking care of yourself

Caregiver Support : Taking care of yourself

FAQs

Patient Affair Directory

Video Library